Novartis accused of owing $47m in IP royalties
15-07-2021
Novartis secures victory as MS drug patent is upheld
18-08-2020
Inventiva and AbbVie extend agreement to develop RORγ inverse agonists
04-09-2017
Duncan_Andison / iStockphoto.com
AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus (HCV) are invalid.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Norvartis, patent, Hepatitis C, SCOTUS, USPTO, declaratory judgment, genes, invalidity, US Supreme Court
